Pharma Focus Asia

Wuxi Biologics to Invest US$60 million to Build a Biologics Manufacturing Unit in Singapore

Introduction:

Wuxi Biologics plans to invest US$60 million in establishing a state-of-the-art biologics manufacturing facility in Singapore.

Features:

The manufacturing facility will be arranged with single-use bioreactors at the next-generation facility. It is majorly designed to support continuous bio-processing.

Next-generation manufacturing technology is to be deployed in the Singapore facility. The company will install bio-processing capabilities for early-stage development.

The company will install up to 4,500L bioreactor capacity at the facility, including two 2,000L traditional fed-batch and one 500L perfusion based continuous processing.

WuXi’s new facility will engage in both clinical and small volume commercial production. It will also include an early-stage bioprocess development lab.

The facility will create around 150 new jobs.

It is expected to be operational by 2022 and will boast 10 facilities with a total bioreactor capacity of 222,700 L.

The facility uses disposable, modular and continuous technology, which is easier to replicate globally than traditional tech and uses lower capex.

Specifications:

NameWuxi Biologics Global Solution Provider
BudgetUS$60 million
LocationSingapore
TypeConstruction
ScheduleTo be operational by 2022
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024